Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Stifel Nicolaus

Research analysts at Stifel Nicolaus began coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $44.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 168.78% from the company’s […]

Leave a Reply

Your email address will not be published.

Previous post Morgan Stanley Boosts Talen Energy (NASDAQ:TLN) Price Target to $430.00
Next post Saia (NASDAQ:SAIA) Raised to “Positive” at Susquehanna